Hemoglobin News and Research

RSS

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed-dose combination ACTOplus met® (pioglitazone HCl and metformin HCl) as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of less than or equal to 7 percent compared to either component alone.

15 Oct 2009

Findings may reveal new treatments for people suffering from chronic hemoglobin levels

A gene with a significant effect on regulating hemoglobin in the body has been identified as part of a genome-wide association study, which looked at the link between genes and hemoglobin level in 16,000 people.

12 Oct 2009

New cancer drugs boost drug spending

Cancer treatments are on track to become the biggest driver of specialty pharmacy spending as its contribution to overall drug spending hit five percent for the first time in the first half of 2009, according to Medco Health Solutions, Inc.

8 Oct 2009

AMAG Pharmaceuticals to present three abstracts at ASN Renal Week meeting

AMAG Pharmaceuticals, Inc. today announced that three abstracts have been accepted for presentation at the American Society of Nephrology (ASN) Renal Week meeting being held October 27-November 1, 2009 in San Diego, CA.

8 Oct 2009

Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight

Results from a 24-week phase 3 clinical study demonstrated that the investigational drug dapagliflozin, added to metformin, demonstrated significant mean reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c) and in the secondary endpoint, fasting plasma glucose (FPG) in patients with type 2 diabetes inadequately controlled with metformin alone, as compared to placebo plus metformin.

3 Oct 2009

Personal approach to psychological well-being

At the World Congress on Psychosomatic Medicine in Torino, Italy, Carol Ryff, Professor of Psychology at the University of Wisconsin, has described how, more than simply feeling happy, it is the personal approach to psychological well-being that matters.

26 Sep 2009

Study reveals that AIR Inhaled Insulin is inferior to SC insulin

The commercial failure of Exubera- (Pfizer, New York, NY), the first inhaled insulin product to come to market, led other companies such as Eli Lilly-Alkermes to halt studies of similar drug delivery in development intended to compete for a share of the lucrative diabetes market. Does this signal defeat for efforts to deliver insulin via the lungs? The science and circumstances behind the Lilly-Alkermes decision to discontinue trials of the AIR- inhaled insulin product are explored in a special supplement to Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The supplement is available free online at www.liebertpub.com/dia

24 Sep 2009

Phase III clinical trial results of DAR-31 published

Gilead Sciences, Inc. today announced the publication of data from DAR-311 (DORADO), a Phase III clinical trial evaluating the company’s once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, defined as the failure to achieve blood pressure goal while adhering to full doses of an appropriate three (or more) drug antihypertensive regimen that includes a diuretic.

14 Sep 2009

Newly discovered molecular circuit helps maintain proper body metabolism

Researchers at the University of Pennsylvania School of Medicine have discovered a molecular circuit involving heme that helps maintain proper metabolism in the body, providing new insights into metabolic disorders such as obesity and diabetes.

14 Sep 2009

Affymax to complete Hematide Phase 3 clinical study by the end of 2009

Affymax, Inc. today announced that it has notified clinical trial sites to complete treatment of patients in the Phase 3 clinical program for the investigational drug, Hematide, by the end of 2009.

10 Sep 2009

Nutrisystem D program helps overweight type 2 diabetic people lose weight

Results from a clinical study conducted at the Temple University School of Medicine and published today in the journal Postgraduate Medicine(1), show that a pre-packaged, portion controlled meal plan helped overweight individuals with type 2 diabetes lose significantly more weight and reduce their A1C test scores (a 90-day measure of blood sugar control) by almost a full point greater than those following a standard hospital-based diabetes support and education program, according to the findings.

9 Sep 2009

U.S. Army awards AWR certification for the Masimo Radical-7 and Rad-57 Pulse CO-Oximeters

Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, today announced that its Radical-7 and Rad-57 Pulse CO-Oximeters have achieved Airworthiness Release (AWR) Certification from the United States Army.

4 Sep 2009

Children's Hospital Oakland converts to Masimo Rainbow SET Pulse CO-Oximetry technology

Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that Children's Hospital & Research Center Oakland has completed its system-wide conversions to Masimo Rainbow SET Pulse CO-Oximetry technology.

2 Sep 2009

Medgenics' EPODURE tissue Biopumps platform technology effective in maintaining hemoglobin levels

Medgenics is pleased to announce that one of the patients, who was treated with the Company’s EPODURE tissue Biopumps almost 11 months ago, continues to be effectively treated for anemia without a single erythropoietin (EPO) injection. This patient (#2) was dependent on frequent injections of the therapeutic protein (EPO) for the 18 months prior to receiving a single administration of 3 tiny EPODURE tissue Biopumps in the Company’s phase I/II anemia trial in Israel.

27 Aug 2009

Haber’s Electromolecular Propulsion technology offers high molecular separation speeds

Haber, Inc. (“Haber”), (OTC: HABE), a Delaware corporation headquartered in Arlington, Mass., with proprietary technologies in the separations sciences and environmentally friendly processing of gold bearing ores, announced today that it has formed a wholly owned subsidiary incorporated in Delaware called “EMP Diagnostics Inc.” (“EDI”). The business of the new company will focus on the application of Haber’s Electromolecular Propulsion technology (EMP). EMP is a separation technology that achieves unrivaled molecular separation speeds and has other unique capabilities not attainable with electrophoresis or liquid chromatography.

27 Aug 2009

DaVita to present three abstracts on Peritoneal Dialysis at the ISPD meeting

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), in conjunction with DaVita Clinical Research(R), today announced that it will present three abstracts at the 3rd North American Chapter meeting of the International Society for Peritoneal Dialysis (ISPD) on August 27-29 in Vancouver, British Columbia.

26 Aug 2009

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.

26 Aug 2009

Masimo SET pulse oximetry technology implemented in Childrens Hospital Los Angeles

Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that Childrens Hospital Los Angeles, ranked by U.S. News & World Report as one of 'America's Best Children's Hospitals', has completed its system-wide conversion to Masimo SET pulse oximetry technology.

26 Aug 2009

GS Gmbh to integrate Masimo Rainbow SET Pulse CO-Oximetry into corpuls patient monitoring modules

Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, and GS Elektromedizinische Gerate G. Stemple GmbH, a German developer and manufacturer of innovative medical equipment for the Emergency Medical Services (EMS), today jointly announced a worldwide technology licensing agreement to integrate Masimo Rainbow SET Pulse CO-Oximetry into corpuls(R) patient monitoring modules. The agreement enables GS GmbH to expand the vital signs and noninvasive measurement capabilities of its defibrillators and patient monitoring systems to help EMS professionals detect and treat life-threatening conditions earlier.

20 Aug 2009

Oxygen treatment may speed memory loss associated with Alzheimer's

A 65-year-old women goes into the hospital for routine hip surgery. Six months later, she develops memory loss and is later diagnosed with Alzheimer's Disease. Just a coincidence? Researchers at the University of South Florida and Vanderbilt University don't think so. They suspect that the culprit precipitating Alzheimer's disease in the elderly women may be a routine administration of high concentrations of oxygen for several hours during, or following, surgery - a hypothesis borne out in a recent animal model study.

12 Aug 2009

Hemoglobin News and Research

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

Findings may reveal new treatments for people suffering from chronic hemoglobin levels

New cancer drugs boost drug spending

AMAG Pharmaceuticals to present three abstracts at ASN Renal Week meeting

Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight

Personal approach to psychological well-being

Study reveals that AIR Inhaled Insulin is inferior to SC insulin

Phase III clinical trial results of DAR-31 published

Newly discovered molecular circuit helps maintain proper body metabolism

Affymax to complete Hematide Phase 3 clinical study by the end of 2009

Nutrisystem D program helps overweight type 2 diabetic people lose weight

U.S. Army awards AWR certification for the Masimo Radical-7 and Rad-57 Pulse CO-Oximeters

Children's Hospital Oakland converts to Masimo Rainbow SET Pulse CO-Oximetry technology

Medgenics' EPODURE tissue Biopumps platform technology effective in maintaining hemoglobin levels

Haber’s Electromolecular Propulsion technology offers high molecular separation speeds

DaVita to present three abstracts on Peritoneal Dialysis at the ISPD meeting

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Masimo SET pulse oximetry technology implemented in Childrens Hospital Los Angeles

GS Gmbh to integrate Masimo Rainbow SET Pulse CO-Oximetry into corpuls patient monitoring modules

Oxygen treatment may speed memory loss associated with Alzheimer's

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News